Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
复制标题
DOI：
10.1016/j.jtho.2017.11.131
复制
发表时间：
2018-04-01
影响因子：
20.4
通讯作者：
Garon, Edward B.
中科院分区：
文献类型：
--
作者：
Felip, Enriqueta;Barlesi, Fabrice;Garon, Edward B.
简介：在这项2期研究中，我们评估了活性AUY922在预治疗的患者与IV期NSCLC。方法：晚期NSCLC患者分为分子定义的层的基础上突变的EGFR基因，ALK受体酪氨酸激酶基因（ALK），KRAS基因，或野生型的所有三个。所有患者必须既往接受过2线以上治疗，但第5层中接受过较少治疗的EGFR队列（EGFR
Introduction: In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC.Methods: Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all three. All patients must have received more than two prior lines of therapy, except for those in a fifth stratum for a less pretreated EGFR cohort (EGFR